The Carmat integral heart prosthesis. (photo credit: Carmat)
Designer and developer of the most advanced total artificial heart project in the world, aimed at offering a therapeutic alternative to patients suffering from end-stage biventricular heart failure, Carmat is launching a fundraiser of around 30 million euros which will benefits from subscription commitments in the amount of 22 million euros
▪ Global offer for specialized and strategic investors as well as retail investors via the PrimaryBid platform
▪ Issue price of the new shares of 10 euros per share
▪ Closing of the PrimaryBid Offer on April 11, 2022 at 10 p.m. and of the Reserved Offer on April 12, 2022 before the opening of the markets
Stéphane Piat, CEO of CARMAT, comments: “The fundraising that we are launching today will strengthen our financial structure and allow us to calmly ensure the resumption of the implantations of our Aeson® artificial heart from October 2022. The dialogue that we are conducting with the competent authorities and the notified body DEKRA, as well as the recent resumption of our production, after the integration of changes that have allowed us to reinforce the robustness of various components, make us indeed confident in our ability to resume our clinical trials and our sales as planned, and thus meet the high expectations of doctors and patients. The support of our historic shareholders is particularly important at this crucial time for the company and I would particularly like to highlight their very strong commitment. I am also happy that we can offer other investors, as well as individuals – via the PrimaryBid platform – the opportunity to contribute to the development of our Company, and of a unique technology which we believe more than ever has the potential to radically and lastingly change the management of patients with end-stage biventricular heart failure. »
Read the full CP